Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

She started treatment with etanercept (Enbrel ®) 1 month previously. One day after a subcutaneous injection into the left thigh, she developed a mildly pruritic eruption on the right thigh ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...